Top in endocrinology: Artificial pancreas for use in pregnancy; food additive emulsifiers

The FDA has authorized CamAPS FX, a closed loop algorithm that links compatible continuous glucose monitors and insulin pumps into an artificial pancreas system for patients with type 1 diabetes aged 2 years and older.

CamAPS FX (CamDiab) is the first of its kind to be authorized in the United States for use during pregnancy, according to a press release from Cambridge University.

“It has been extensively tested, and we’re proud that it is considered by many to be the best algorithm out there,” Roman Hovorka, PhD, a professor of metabolic technology at the Institute of Metabolic Science and department of pediatrics at the University of Cambridge, said in the release.

It was the top story in endocrinology last week.

In another top story, researchers found that higher intake of eight types of food additive emulsifiers was linked to an increased risk for type 2 diabetes.

Read these and more top stories in endocrinology below:

FDA OK’s first artificial pancreas for managing type 1 diabetes during pregnancy

The FDA authorized a closed-loop algorithm for an artificial pancreas system for use by people with type 1 diabetes aged 2 years and older, including during pregnancy, according to press release from Cambridge University. Read more.

Eating more foods containing additive emulsifiers may raise risk for type 2 diabetes

Adults in France who consumed more food additive emulsifiers had increased risk for type 2 diabetes, according to a study published in The Lancet Diabetes & Endocrinology. Read more.

Adults with obesity, preexisting CVD maintain weight loss with semaglutide at 4 years

Adults with obesity lost 10.2% of their body weight at 4 years with the GLP-1 receptor agonist semaglutide, according to an analysis of data from the SELECT trial. Read more.

GLP-1s not tied to higher risk for surgical complications for adults with diabetes

Adults with diabetes who used a GLP-1 receptor agonist and underwent surgery requiring general anesthesia had similar odds for postsurgical complications as those receiving other oral diabetes medications, according to study data. Read more.

Most transgender teens reach adult height close to their sex assigned at birth after HT

Most transgender adolescents receiving a gonadotropin-releasing hormone agonist combined with gender-confirming hormone therapy grow to an adult height close to the reference height for their sex assigned at birth, according to study data. Read more.